VVM
OCUL icon

Versant Venture Management’s Ocular Therapeutix OCUL Stock Holding History

Versant Venture Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,465,384
Closed -$30.3M – 12
2020
Q4 		$30.3M Sell
1,465,384
-750,000
-34% -$11.1M 3.15% 6
2020
Q3 		$16.9M Hold
2,215,384
– – 3.09% 7
2020
Q2 		$18.5M Hold
2,215,384
– – 2.65% 8
2020
Q1 		$11M Hold
2,215,384
– – 3.01% 6
2019
Q4 		$8.75M Hold
2,215,384
– – 2.64% 4
2019
Q3 		$6.73M Hold
2,215,384
– – 2.61% 5
2019
Q2 		$9.75M Hold
2,215,384
– – 2.84% 5
2019
Q1 		$8.8M Hold
2,215,384
– – 2.9% 5
2018
Q4 		$8.82M Hold
2,215,384
– – 4.36% 4
2018
Q3 		$15.2M Hold
2,215,384
– – 5.18% 4
2018
Q2 		$15M Hold
2,215,384
– – 4.67% 3
2018
Q1 		$14.4M Hold
2,215,384
– – 4.61% 4
2017
Q4 		$9.86M Hold
2,215,384
– – 10.37% 3
2017
Q3 		$13.8M Hold
2,215,384
– – 10.54% 4
2017
Q2 		$20.5M Hold
2,215,384
– – 16.15% 4
2017
Q1 		$20.6M Hold
2,215,384
– – 14.95% 4
2016
Q4 		$18.5M Hold
2,215,384
– – 18.05% 2
2016
Q3 		$15.2M Hold
2,215,384
– – 16.97% 3
2016
Q2 		$11M Hold
2,215,384
– – 11.11% 2
2016
Q1 		$21.4M Hold
2,215,384
– – 15.45% 3
2015
Q4 		$20.8M Hold
2,215,384
– – 12.15% 3
2015
Q3 		$31.1M Buy
+2,215,384
New +$44.5M 17.86% 3

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Versant Venture Management's OCUL Position: Q1 2021 in Review

Versant Venture Management sold out of Ocular Therapeutix (OCUL) in Q1 2021, closing a stake of 1,465,384 shares — an estimated $30.3M sold.

Versant Venture Management first reported a position in OCUL in Q3 2015 and held it in 22 quarters. The position peaked at $31.1M in Q3 2015. 154 funds tracked by Wall St. Rank hold OCUL as of Q1 2021.

  • Versant Venture Management reported no remaining Ocular Therapeutix position as of Q1 2021 after selling out during the quarter.
  • Versant Venture Management sold 1,465,384 Ocular Therapeutix shares in Q1 2021, an estimated $30.3M.
  • Versant Venture Management first reported a position in Ocular Therapeutix in Q3 2015 and held it in 22 quarters.
  • Versant Venture Management's Ocular Therapeutix position peaked at $31.1M in Q3 2015.
  • 154 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2021.

Based on Versant Venture Management's 13F filing for Q1 2021, filed 7 May 2021.